ATS 2019 Virtual Final Program

11:00 Difficult Cases Discussion 1 A.P. Ruhl, MD, MHS, Bethesda, MD 11:30 Question and Answer Period #2 11:40 LUNCH 12:20 Venous Thromboembolism in SCD E.S. Klings, MD, Boston, MA 12:45 How I Manage Dyspnea and Hypoxia in SCD R.F. Machado, MD, Indianapolis, IN 1:10 Why Sleep and Sleep Disordered Breathing Matter in SCD C.L. Rosen, MD, Cleveland, OH 1:35 Question and Answer Period #3 1:45 Break 1:55 Real World Screening, Evaluation, and Management of Pulmonary Hypertension (PH) in SCD A.A. Desai, MD, Indianapolis, IN 2:20 Cases from Jamaica: A Pulmonologist’s Approach to SCD in Low-Resource Settings J.M. Knight-Madden, MBBS, PhD, Kingston, Jamaica 2:45 Difficult Cases Discussion 2 E.S. Klings, MD, Boston, MA 3:15 How I Set Up a Multidisciplinary SCD Pulmonary Clinic E.S. Klings, MD, Boston, MA R.T. Cohen, MD, MPH, Boston, MA 3:35 Panel Discussion on Multidisciplinary Sickle Cell Pulmonary Clinics E.S. Klings, MD, Boston, MA R.T. Cohen, MD, MPH, Boston, MA 3:50 Questions and Answers and Closing Remarks A.P. Ruhl, MD, MHS, Bethesda, MD CLINICAL POSTGRADUATE COURSE CME Credits Available: 6.5 PG8 PROCEEDINGS FROM THE WORLD SYMPOSIUM 2018: WHAT DO WE NEED TO KNOW MOVING FORWARD? R Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $350 In-Training Member: $200 Non-Member: $425 In-Training Non-Member: $300 : Registrants must bring a laptop to the course to view the course material. Assembly on Pulmonary Circulation 8:00 a.m. - 4:00 p.m. KBHCCD Room C147/C154 (Level 1) Target Audience Residents, fellows, pulmonologists, nurse practitioners, physician assistants, cardiologists, early career professionals, nurses Objectives At the conclusion of this session, the participant will be able to: • diagnose different types of pulmonary hypertension, able to differentiate all groups of pulmonary hypertension and prevent misdiagnosis; • gain new strategies to manage the care of pulmonary hypertension, will know how to manage group 2, 3, 4 and 5 pulmonary hypertension; • integrate new treatment options in discussing pulmonary hypertension with patient, and review newer treatment options for other groups of Pulmonary Hypertension (ie group 2,3 and 4). In this session, the audience will learn about the importance of recognizing the different types of pulmonary hypertension and the impact this distinction has on the management of the disease. Speakers will present relevant information from the updated pulmonary hypertension proceedings, published in December 2018. Chairing: T. Lahm, MD, Indianapolis, IN V. De Jesus Perez, MD, ATSF, Palo Alto, CA M. Humbert, MD, PhD, Bicetre, France S. Sahay, MD, Houston, TX 8:00 Introduction T. Lahm, MD, Indianapolis, IN 8:10 Newer World Symposium Guidelines 2018 on Treatment and Diagnosis of PAH M. Humbert, MD, PhD, Bicetre, France 8:40 Bench to Bedside: Pathogenesis of Different Types of PH M. Rabinovitch, MD, Stanford, CA 9:10 Idiopathic PAH: How You Rule Out Other Conditions? A.R. Tonelli, MD, Cleveland, OH 9:40 Heritable PAH: Is Genetic Testing Necessary M. Aldred, PhD, Indianapolis, IN 10:10 Break 10:20 PVOD: Why I Know So Little About It? D. Montani, MD, PhD, Le Kremlin Bicêtre, France 10:50 CHD PAH: Differences Between Types of CHD V. De Jesus Perez, MD, ATSF, Palo Alto, CA 11:20 CTD PAH: How to Differentiate Group I from III PH K.M. Chin, MD, Dallas, TX 11:50 LUNCH 12:50 Group 2 PH: How to Prevent Misdiagnosis? T. Thenappan, MD, Minneapolis, MN 1:15 Group 3 PH: Why the Degree of Precapillary PH Varies? H.R. Cajigas, MD, Chicago, IL 1:40 How COPD PH Is Different from ILD-PH R. Raj, MD, Palo Alto, CA 2:00 Treatment of PAH: Updates from the Proceedings I.R. Preston, MD, Boston, MA 2:25 Break 2:35 PoPH: The Necessary Components for Its Diagnosis S. Sahay, MD, Houston, TX ATS 2019 • Dallas, TX FRIDAY • MAY 17 7 FRIDAY